These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18986288)

  • 21. HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study.
    Christensen D; Feldman C; Rossi P; Marrie T; Blasi F; Luna C; Fernandez P; Porras J; Martinez J; Weiss K; Levy G; Lode H; Gross P; File T; Ramirez J;
    Clin Infect Dis; 2005 Aug; 41(4):554-6. PubMed ID: 16028168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Etiology of community-acquired pneumonia in immunocompetent adults].
    Moreno B R; Riquelme O R
    Rev Chilena Infectol; 2005; 22 Suppl 1():s18-25. PubMed ID: 16163415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in the etiology of community-acquired pneumonia according to site of care: a population-based study.
    Almirall J; Boixeda R; Bolíbar I; Bassa J; Sauca G; Vidal J; Serra-Prat M; Balanzó X;
    Respir Med; 2007 Oct; 101(10):2168-75. PubMed ID: 17629472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
    Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
    J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia.
    Singer M; Nambiar S; Valappil T; Higgins K; Gitterman S
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S216-24. PubMed ID: 18986293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of recent studies of community-acquired pneumonia.
    Higgins K; Singer M; Valappil T; Nambiar S; Lin D; Cox E
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S150-6. PubMed ID: 18986282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
    Bartlett JG
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.
    File TM; Schentag JJ
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S157-65. PubMed ID: 18986283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Microbiologic diagnosis of community-acquired pneumonia in adults].
    Jiménez P P; Calvo A M
    Rev Chilena Infectol; 2005; 22 Suppl 1():s32-8. PubMed ID: 16163417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diagnosis and therapy of community-acquired pneumonia].
    Speich R; Ruef C; Russi EW
    Schweiz Med Wochenschr; 1993 Oct; 123(39):1846-56. PubMed ID: 8211038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One drug or two? Step-down therapy after i.v. antibiotics for community-acquired pneumonia.
    Harrington Z; Barnes DJ
    Intern Med J; 2007 Nov; 37(11):767-71. PubMed ID: 17908087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early and late treatment failure in community-acquired pneumonia.
    Garcia-Vidal C; Carratalà J
    Semin Respir Crit Care Med; 2009 Apr; 30(2):154-60. PubMed ID: 19296415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Community acquired pneumonia of hospitalised patient in the ordinary ward].
    Scala R
    Clin Ter; 2004; 155(7-8):293-303. PubMed ID: 15553257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
    Martin M; Moore L; Quilici S; Decramer M; Simoens S
    Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Community-acquired pneumonia.
    Carbonara S; Monno L; Longo B; Angarano G
    Curr Opin Pulm Med; 2009 May; 15(3):261-73. PubMed ID: 19387263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
    Simoens S
    Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How long should we treat community-acquired pneumonia?
    Scalera NM; File TM
    Curr Opin Infect Dis; 2007 Apr; 20(2):177-81. PubMed ID: 17496577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network.
    Welte T; Köhnlein T
    Semin Respir Crit Care Med; 2009 Apr; 30(2):127-35. PubMed ID: 19296412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Community-acquired pneumonia: the U.S. perspective.
    Niederman MS
    Semin Respir Crit Care Med; 2009 Apr; 30(2):179-88. PubMed ID: 19296418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical end points of therapy for patients with mild community-acquired pneumonia.
    Gilbert DN
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S140-4. PubMed ID: 18986280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.